Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
| PINNACLE FINANCIAL PARTNERS INCPNFP · Entity 70624 | Director | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,656 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 63,656 |
PINNACLE FINANCIAL PARTNERS INC
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PNFP Common StockSEC Table I · non-derivative | Direct | 24,168 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Tax withholding · Disposed 239 · Balance 23,179 F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Row 2 · 2024-03-01 · Grant · Acquired 989 · Balance 24,168 F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. |
| Depositary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2024-03-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards.
F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves.
F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.44 | $158.60 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,181 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 24, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.38 | $154.70 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,116 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 21, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.49 | $161.85 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,051 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 20, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.44 | $158.60 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,986 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 19, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.42 | $157.30 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,921 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 18, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.46 | $159.90 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,856 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 17, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.33 | $151.45 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,791 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 14, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.31 | $150.15 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,726 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 13, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.38 | $154.70 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,661 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 12, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.49 | $161.85 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,596 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 11, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.48 | $161.20 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,531 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 10, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.53 | $164.45 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,466 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 07, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.66 | $172.90 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,401 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 06, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.65 | $172.25 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,336 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 05, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.58 | $167.70 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,271 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 04, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.61 | $169.65 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,206 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 03, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.54 | $165.10 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,141 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 30, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.61 | $169.65 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,076 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 29, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.51 | $163.15 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,011 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 28, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.52 | $163.80 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,946 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 27, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.57 | $167.05 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 30 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,881 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 27, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.57 | $167.05 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,881 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 26, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.49 | $161.85 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 29 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,816 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 23, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.55 | $165.75 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 28 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,751 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 22, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.51 | $163.15 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 27 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,686 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 21, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.59 | $168.35 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 26 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,621 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 20, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.54 | $165.10 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,556 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 19, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.56 | $166.40 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,491 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 16, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.49 | $174.30 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,426 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 15, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.47 | $172.90 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,356 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 14, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.51 | $175.70 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,286 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 13, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.45 | $171.50 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,216 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 12, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.46 | $172.20 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,146 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 09, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.21 | $154.70 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,076 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 08, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.22 | $88.80 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,036 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 07, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.24 | $156.80 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,966 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 06, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.15 | $150.50 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,896 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 02, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.42 | $169.40 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,826 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 01, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.39 | $167.30 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,756 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 31, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.36 | $165.20 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,686 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 30, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.38 | $166.60 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,616 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 29, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 70 | $2.44 | $170.80 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,546 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 26, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.55 | $165.75 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,476 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 25, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.62 | $170.30 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,411 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 24, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.59 | $168.35 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,346 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 23, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.59 | $168.35 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,281 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 22, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.51 | $163.15 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,216 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 19, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.35 | $152.75 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,151 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 18, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.23 | $144.95 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,086 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 17, 2022 Filed Sep 30, 2022 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.31 | $150.15 |
DisclosureSEC source: 0001209191-22-051667 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,021 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.